Ivana Sullivan

1.2k total citations · 1 hit paper
55 papers, 686 citations indexed

About

Ivana Sullivan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ivana Sullivan has authored 55 papers receiving a total of 686 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Ivana Sullivan's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Ivana Sullivan is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Ivana Sullivan collaborates with scholars based in Spain, France and United States. Ivana Sullivan's co-authors include Mariona Riudavets, David Planchard, Margarita Majem, Agustí Barnadas, Juliana Salazar, David Páez, Montserrat Baiget, Joaquín Mosquera, Elisabeth del Río and Geòrgia Anguera and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Molecular Sciences.

In The Last Decade

Ivana Sullivan

51 papers receiving 684 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03

2025 18 citations Afshin Dowlati, Anne C. Chiang et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Ivana Sullivan

Since Specialization

Citations

This map shows the geographic impact of Ivana Sullivan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivana Sullivan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivana Sullivan more than expected).

Fields of papers citing papers by Ivana Sullivan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivana Sullivan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivana Sullivan. The network helps show where Ivana Sullivan may publish in the future.

Co-authorship network of co-authors of Ivana Sullivan

This figure shows the co-authorship network connecting the top 25 collaborators of Ivana Sullivan. A scholar is included among the top collaborators of Ivana Sullivan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivana Sullivan. Ivana Sullivan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03 breakdown → 2025 ·Journal of Thoracic Oncology ·Afshin Dowlati, Anne C. Chiang, Andrés Cervantes, Sunil Babu, Erika Hamilton, (unknown), Andrea Tazbirkova, Ivana Sullivan, Cédric van Marcke, Antoîne Italiano, (unknown), Sabeen Mekan, (unknown), Saiama N. Waqar	18
2	ERCC1 and ERCC2 Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer 2024 ·Pharmaceutics ·(unknown), Laura López-Vilaró, (unknown), Margarita Majem, (unknown), (unknown), María J. Arranz, Juliana Salazar, Ivana Sullivan	1
3	EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers 2024 ·npj Precision Oncology ·Marco Tagliamento, Marie Morfouace, (unknown), Júlio Oliveira, Laurent Greillier, Judith Raimbourg, Anne‐Claire Toffart, Thierry Chatellier, Nicolas Cloarec, Ivana Sullivan, Birutė Brasiūnienė, M. Duruisseaux, Kersti Oselin, (unknown), (unknown), (unknown), Jean‐Yves Blay, Benjamin Besse, Nicolas Girard	6
4	Difficulties on the access to innovative targeted therapies for lung cancer in Spain 2023 ·Clinical & Translational Oncology ·Virginia Calvo, Carlos Camps, Enric Carcereny, Manuel Cobo, Manuel Dómine, M.R. García Campelo, J.L. González-Larriba, M. Guirado, Florentino Hernándo, Bartomeu Massutí, Ernest Nadal, Delvys Rodríguez‐Abreu, (unknown), Ivana Sullivan, Mariano Provencio, (unknown)	3
5	1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor 2023 ·Annals of Oncology ·Laura Mezquita, (unknown), (unknown), (unknown), Ernest Nadal, (unknown), (unknown), Santiago Ponce Aix, Ivana Sullivan, Antonio Calles, Nicolas Cloarec, (unknown), Thierry Berghmans, R. Descourt, Lizza Hendriks, Pilar Garrido, Åslaug Helland, Enric Carcereny, Benjamin Besse, Anne‐Marie C. Dingemans	1
6	Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain 2023 ·BMC Pulmonary Medicine ·Javier de Castro, Amelia Insa, Roberto Collado‐Borrell, Vicente Escudero‐Vilaplana, Alex Martínez‐Martí, Elena Fernández, Ivana Sullivan, (unknown), (unknown), (unknown)	6
7	Detecting ALK , ROS1 , and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA ‐based techniques 2023 ·Molecular Oncology ·Ana Giménez‐Capitán, Estela Sánchez‐Herrero, (unknown), (unknown), Ivana Sullivan, Virginia Calvo, (unknown), Santiago Viteri, (unknown), Cristina Aguado, (unknown), (unknown), Clara Mayo‐de‐las‐Casas, Noemı́ Reguart, Rafael Rosell, Mariano Provencio, Atocha Romero, Miguel Ángel Molina‐Vila	8
8	Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events 2022 ·International Journal of Molecular Sciences ·(unknown), Geòrgia Anguera, Carlos Zamora, (unknown), Laura Martínez‐Martínez, (unknown), Ivana Sullivan, (unknown), Margarita Majem, Sílvia Vidal	11
9	SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021) 2022 ·Clinical & Translational Oncology ·Jordi Remón, Reyes Bernabé, Pedro Diz Dios, Enriqueta Felip, J.L. González-Larriba, M. Lázaro, Xabier Mielgo-Rubio, (unknown), Ivana Sullivan, (unknown)	7
10	Circulating leukocyte–platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents 2021 ·Cancer Immunology Immunotherapy ·Carlos Zamora, Mariona Riudavets, Geòrgia Anguera, (unknown), Ivana Sullivan, (unknown), (unknown), Ma Àngels Ortiz, Pablo Gallardo, Lídia Perea, (unknown), Agustí Barnadas, Margarita Majem, Sílvia Vidal	9
11	SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019) 2020 ·Clinical & Translational Oncology ·Manuel Dómine, Teresa Morán, Dolores Isla, Juan Luis Gomez Marti, Ivana Sullivan, Mariano Provencio, M.E. Olmedo, Santiago Ponce, Ana Blasco, Manuel Cobo	40
12	1417TiP Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic NSCLC: The ETOP CHESS trial 2020 ·Annals of Oncology ·Matthias Gückenberger, Isabelle Opitz, Urania Dafni, (unknown), (unknown), Olgun Eliçin, Alfredo Addeo, Joachim G.J.V. Aerts, Anne‐Marie C. Dingemans, Lizza Hendriks, B. Munárriz, Óscar Juan, Ivana Sullivan, Javier Valdivia, (unknown), Heidi Roschitzki‐Voser, Stefanie Ehrbar, (unknown), Solange Peters, Rolf A. Stahel	1
13	Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents 2020 ·Frontiers in Oncology ·Mariona Riudavets, Joaquín Mosquera, Rosario García‐Campelo, (unknown), Geòrgia Anguera, Pablo Gallardo, Ivana Sullivan, (unknown), (unknown), Agustí Barnadas, Ignasi Gich, Margarita Majem	41
14	P1.07-09 Implementation of a Nursing Program for Cancer Patients Treated with Immunotherapy by an Immunotherapy Nurse Specialist 2019 ·Journal of Thoracic Oncology ·J. M. Serra, Margarita Majem, Ivana Sullivan, Mariona Riudavets, Geòrgia Anguera, (unknown), (unknown), (unknown)	2
15	P2.04-52 Impact of Corticosteroids and Antibiotics on Efficacy of Immune-Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer 2019 ·Journal of Thoracic Oncology ·Mariona Riudavets, Joaquín Mosquera, Rosario García Campelo, (unknown), Geòrgia Anguera, Pablo Gallardo, Ivana Sullivan, (unknown), Margarita Majem	4
16	Prognostic effect of VEGF gene variants in metastatic non-small-cell lung cancer patients 2019 ·Angiogenesis ·Ivana Sullivan, (unknown), (unknown), Albert Altés, Margarita Majem, Remei Blanco, (unknown), (unknown), Agustí Barnadas, Juliana Salazar	28
17	P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients 2018 ·Journal of Thoracic Oncology ·Laura Mezquita, Santiago Ponce Aix, Édouard Auclin, Alejandro Navarro, David Planchard, Ivana Sullivan, Gérard Zalcman, Julien Mazières, Lizza Hendriks, Caroline Caramella, Margarita Majem, Pernelle Lavaud, (unknown), Enriqueta Felip, Luis Paz‐Ares, Benjamin Besse	1
18	Pharmacogenetic clinical randomized phase II trial to evaluate the efficacy and safety of FOLFIRI with high dose of irinotecan (FOLFIRI-HD) in metastatic colorectal cancer patients according to UGT1A 1 genotype 2017 ·Annals of Oncology ·David Páez, (unknown), Ana Sebio, (unknown), (unknown), A.C. Virgili Manrique, (unknown), Ivana Sullivan, Juliana Salazar	1
19	SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients 2017 ·Medical Oncology ·(unknown), Juliana Salazar, María J. Arranz, Ana Sebio, Josefina Móra, Ivana Sullivan, (unknown), Marta Martín-Richard, Agustí Barnadas, Montserrat Baiget, David Páez	6
20	¿Existe un límite para el abordaje laparoscópico de la masa residual retroperitoneal posquimioterapia? 2015 ·Actas Urológicas Españolas ·Josep María Gaya, Joan Palou, J.A. Peña, Antonio Rosales, Pablo Maroto, Ivana Sullivan, H. Villavicencio	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact